Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bcl-2

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    55 result(s) found for: Bcl-2. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2004-003906-81 Sponsor Protocol Number: A7-2 Start Date*: 2005-01-14
    Sponsor Name:Oncology Institute of Vilnius University
    Full Title: Chemoradiation with once weekly gemcitabine for invasive bladder cancer
    Medical condition: Invasive transitional cell bladder cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000106-37 Sponsor Protocol Number: 37.07.-92906 Start Date*: 2008-08-28
    Sponsor Name:Klinik für Dermatologie und Allergologie der RUB, St. Josef Hospital
    Full Title: Studies on the combined treatment using etanercept and ultraviolet B for patients with moderate to severe psoriasis vulgaris
    Medical condition: Psoriasis vulgaris (Plaque-Typ)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004741-17 Sponsor Protocol Number: SPC2996-101 Start Date*: 2005-05-09
    Sponsor Name:Santaris Pharma
    Full Title: SPC2996 in Chronic Lymphocytic Leukaemia An open-labelled, international multicenter dose escalating, phase I/II study of SPC2996, an LNA antisense molecule against Bcl-2, in patients with relapsed...
    Medical condition: Chronic Lymphocytic Leukaemia (CLL) is the most common leukaemia in adults in the US and most of Western Europe. The incidence is 8100 to 12500 new cases in the US per year. CLL is a relatively ind...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000439-14 Sponsor Protocol Number: M13-833 Start Date*: 2018-03-08
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies
    Medical condition: In Part 1 patients with any relapsed or refractory tumor will be eligible to enroll. During Part 2 patients with the following malignancies: acute lymphoblastic leukemia (ALL), acute myeloid leu...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-004630-29 Sponsor Protocol Number: FIL_VERT Start Date*: 2018-06-15
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: A phase II, open label, multicenter trial of Venetoclax (ABT-199/GDC-0199) as single agent in patients with relapsed/refractory BCL-2 positive peripheral T cell lymphoma not otherwise specified (PT...
    Medical condition: Patients with relapsed/refractory BCL-2 positive peripheral T cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and other nodal T-cell lymphomas of T-folli...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042980 T-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042979 T-cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006782-83 Sponsor Protocol Number: EC08/00230 Start Date*: 2013-09-24
    Sponsor Name:Hospital Universitario Virgen de las Nieves
    Full Title: Prevention MODS by modulating the inflammatory response through melatonin administration in surgical patients with severe sepsis.
    Medical condition: Septic patients of abdominal surgery
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005439-26 Sponsor Protocol Number: NL47392.068.13 Start Date*: 2014-04-23
    Sponsor Name:Maastricht University Medical Centre
    Full Title: Topical sinecatechins ointment in treatment of primary superficial Basal Cell Carcinoma: a double blind, randomized, placebo-controlled trial.
    Medical condition: Primary histological proven superficial basal cell carcinoma ≥ 4mm < 20mm outside the H-zone of the face or scalp
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10042503 Superficial basal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001676-11 Sponsor Protocol Number: FIL_MIRO Start Date*: 2014-10-28
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: "MIRO" study (Molecularly Oriented Immuno-radio-therapy): a multicenter phase II trail for the treatment on molecular basis of stage I / II Follicular Lymphoma with local radiotherapy with / witho...
    Medical condition: Stage I/II Follicular Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001084-27 Sponsor Protocol Number: APAC Start Date*: 2006-06-16
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALI GALLIERA
    Full Title: Phase I/II study of prevention of Colorectal Cancer CRC with Allopurinol in High-Risk Subjects
    Medical condition: CHEMOPREVENTION OF COLORECTAL CANCER
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048832 Colon adenoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004110-17 Sponsor Protocol Number: BO18414 Start Date*: 2005-03-29
    Sponsor Name:Roche Products Limited
    Full Title: Full title of the trial : An open-label, multicentre, dose-escalating phase I/II trial of 3-weekly rhuMAb 2H7 in patients with follicular non Hodgkin’s lymphoma
    Medical condition: follicular non-Hodgkin’s lymphoma (NHL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004200-35 Sponsor Protocol Number: CO41863 Start Date*: 2020-07-24
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: A PHASE Ib/II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF VENETOCLAX IN COMBINATION WITH TRASTUZUMAB EMTA...
    Medical condition: Locally advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001102-29 Sponsor Protocol Number: 7100 Start Date*: 2020-07-03
    Sponsor Name:Department of Internal Medicine Vejle Hospital
    Full Title: Venetoclax and Dexamethasone in translocation (11;14) positive relapsed and refractory multiple myeloma (VICTORIA)
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-003619-29 Sponsor Protocol Number: 2005-050 Start Date*: 2008-07-07
    Sponsor Name:Organisation name was not entered
    Full Title: Vaccination med peptider deriveret fra anti-apoptotiske proteiner i Bcl-2 familien, administreret i kombination med adjuvant (Montanide ISA-51) i relation til proteasomhæmmerbehandling af patiente...
    Medical condition: Myelomatose med andet eller senere relaps af sygdommen.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001062-41 Sponsor Protocol Number: 13-005 Start Date*: 2013-06-12
    Sponsor Name:RWTH Aachen University, represented by the Rector, himself represented by Clinical Trial Center (CTC-A) [...]
    1. RWTH Aachen University, represented by the Rector, himself represented by Clinical Trial Center (CTC-A)
    2. RWTH Aachen University, represented by the Rector, himself represented by Clinical Trial Center (CTC-A)
    3. RWTH Aachen University, represented by the Rector, himself represented by Clinical Trial Center (CTC-A)
    Full Title: Neoadjuvant chemotherapy with Cabazitaxel in high risk prostate cancer patients prior to radical prostatectomy
    Medical condition: high-risk prostata cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004340-30 Sponsor Protocol Number: M15-538 Start Date*: 2020-06-08
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-001016-51 Sponsor Protocol Number: 05-UTROGEL-01 Start Date*: 2006-02-28
    Sponsor Name:Karolinska Hospital
    Full Title: In vivo effects of transdermal Estradiol+ oral Progesterone vs oral Conjugated Equine Estrogens + MedroxyProgesteroneAcetate on normal human breast cells proliferation: a randomized comparative study
    Medical condition: Menopausal symptoms
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001288-26 Sponsor Protocol Number: DASAHIVCURE Start Date*: 2022-08-18
    Sponsor Name:IDIBAPS
    Full Title: Safety, tolerance and antiretroviral activity of dasatinib: a pilot clinical trial in patients with recent HIV-1 infection
    Medical condition: Recent HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10058427 Primary HIV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003838-15 Sponsor Protocol Number: 82/2006/O/Sper Start Date*: 2006-09-12
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: CETUXIMAB IN COMBINATION WITH CISPLATIN PLUS DOCETAXEL TO EVALUATE THE ACTIVITY AND SAFETY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA: PHAS...
    Medical condition: Advanced or metastatic gastric and gastroesophageal junction adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056267 Gastroesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003959-11 Sponsor Protocol Number: 1703001 Start Date*: 2020-05-25
    Sponsor Name:Vestre Viken Trust
    Full Title: MUscle Side-Effects of atorvastatin in coronary patients (MUSE) follow-up study
    Medical condition: Coronary heart disease patients With perceived statin Associated muscle symptoms or statin discontinuaton due to muscle symptoms
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004985-27 Sponsor Protocol Number: HO139 Start Date*: 2016-09-29
    Sponsor Name:HOVON Foundation
    Full Title: A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of obinutuzumab (Gazyvaro) followed by obinutuzumab and venetoclax, foll...
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 09:41:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA